Thomas Stephen Basil 4

What Happened Thomas Stephen Basil, a director of Climb Bio, Inc. (CLYM), received a grant of 40,000 derivative shares on June 5, 2026. The reported acquisition price is $0.00, so the immediate cash value reported on the Form 4 is $0. This was an award/grant (derivative) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-08.
• Transaction type: Grant / award of derivative securities (code A).
• Shares awarded: 40,000; reported acquisition price: $0.00; reported value: $0.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: The award vests on the earlier of June 5, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to Basil’s continued service through such date.
• Filing timeliness: Form lists filing date 2026-06-08; no late-filing flag shown in the provided data.

Context This was a compensation-style equity award (a derivative grant) for a director—not an open-market buy or a sale. Such awards are typically for retention or compensation and do not by themselves indicate immediate buying or selling pressure. The award is subject to vesting conditions (see footnote) and there is no indication the shares were exercised or sold.